Ivosidenib

Drug Profile

Ivosidenib

Alternative Names: AG 120

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Cholangiocarcinoma
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 07 Aug 2017 Agios Pharmaceuticals initiates an expanded-access programme for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater, In children, In adolescents, In adults, In the elderly) (PO) (NCT03245424)
  • 15 Jun 2017 Agios Pharmaceuticals plans to initiate the phase III AGILE trial in Acute myeloid leukaemia (First-line therapy, Combination therapy) (PO) (NCT03173248)
  • 03 Jun 2017 Updated adverse events, efficacy and pharmacodynamics data from a phase I trial in Solid tumours presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top